Treatment in the Add-Aspirin Trial

Participants in the Add-Aspirin trial take either aspirin or a placebo once a day for up to five years.

See below for more about the treatments used in Add-Aspirin.

What is a placebo?

A placebo is a "dummy" tablet. It looks like an aspirin tablet but it doesn't contain any medicine. We are using a placebo in this study so that we can make as clear an assessment as possible about the effects of aspirin. To make sure the results are as reliable as possible, neither the participants, nor the doctors, will know or be able to choose who is taking aspirin and who is taking a placebo.

back to top

Run-in treatment

Aspirin is a common, frequently used drug and most people take it without experiencing any side effects. However, a key aspect of any clinical trial is protecting the safety of the participants. In order to help us identify people for whom regular aspirin use may not be suitable, all Add-Aspirin participants are asked to take a 100mg aspirin tablet once a day for about eight weeks at the beginning of the study. This phase of the study is called the run-in. Participants who do not want to carry on taking tablets every day or who experience side effects may be advised not to continue taking part.

back to top

Study treatment

Participants who continue to take part in the study after the run-in are randomly assigned by a computer to take either aspirin or a placebo, which they will take once a day for up to five years. All participants have a two out of three chance of receiving aspirin. Some participants receive 300mg aspirin whilst others receive 100mg. Using different doses allows us to investigate how much aspirin may be needed to have an effect, if any, against cancer. To make the assessment of aspirin as reliable as possible, in this phase of the study neither participants nor their doctors know which treatment they are taking. However, all NHS doctors can find out which treatment a participant is taking if they need to in a medical emergency. This is known as unblinding.

back to top

Taking the treatment

Add-Aspirin participants take one tablet once a day, every day for up to five years. Tablets should be swallowed whole with plenty of water, preferably after a meal. It is very important that the tablets are taken every day. It is usually easier to remember to do this if the tablet is taken at the same time each day. If you forget to take a tablet, do not take additional tablets to catch up, you should only take one tablet a day.

back to top

Other medications

It is extremely important that Add-Aspirin trial participants do not take other medications that contain aspirin regularly whilst they are taking part in the study. It is also important that participants do not take aspirin bought from a chemist or shop. This may be unsafe and could also interfere with the results of the study. In many cases, alternative medications that do not contain aspirin are available. Your study doctor or GP will be able to advise on this. See below for more information on what medications to avoid.

The following medications should not be taken at the same time as the Add Aspirin trial medication. If you are unsure whether you can take a medication please discuss with your doctor.

Any medications that contain aspirin, which include: Nu-seals, Anadin, Beechams powders, Alka-seltzer, Disprin, Codis 500

Anti-coagulation medication, which include: Warfarin, Acenocoumarol, Phenindione, Dabigatran, Unfractionated Heparin, Low molecular weight heparin*, Rivaroxaban, Apixaban, Argatroban
*In some situations low molecular weight heparin may be permitted when prescribed as to prevent blood clots- please discuss with your doctor.

Anti-platelet medication, which include: Clopidogrel, Dipyridamole, Prasugrel, Ticagrelor, Abciximab, Tirofiban, Eptifibatide, Epoprostenol, Fondaparinaux

Other medications: Methotrexate


The following medications should not be taken regularly or long-term, but are permitted for short-term use. If you plan to take any of the following medications please discuss with your doctor first:

Non-Steroidal Anti-Inflammatory Drugs (NSAID) which include: Ibuprofen, Naproxen, Diclofenac , Acelofenac, Fenoprofen, Flurbiprofen, Ketoprofen, Dexketoprofen, Tiaprofenic acid, Etodolac, Indomethacin, Meloxicam, Tenoxicam, Nabumetone, Phenylbutazone, Ketorolac, Piroxican, Sulindac, Tolfenamic acid, Celecoxib, Etoricoxib

Corticosteroids, which include: Dexamethasone, Prednisolone, Hydrocortisone

Contact Details

If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.

For healthcare professionals

Please log into the members area for Add-Aspirin contact details.

Register Interest

For healthcare professionals

If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk

Register a participant

From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.

To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.

Unblind a participant in the UK

Unblind a participant in the RoI

Unblind a participant in India